1. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment;Stöhr;Br J Anaesth,2021
2. European Medicines Agency. Byfavo: EPAR - Product information 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/byfavo-epar-product-information_en.pdf (accessed 19 August 2022).
3. Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia;Dai;Minerva Anestesiol,2021
4. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial;Doi;J Anesth,2020
5. Quality of recovery after general anesthesia with remimazolam in patients undergoing urologic surgery: a randomized controlled trial comparing remimazolam with propofol;Mao;Drug Des Devel Ther,2022